中文
| Catalogue |
| Recommend Products |
Company News
- AMSBIO: Advanced Tools for Glycobiology Research 11/17/2021
- AMSBIO: Generating Cell Repellent Surfaces in Microfluidic Devices 10/29/2021
- AMSBIO: Novel Assay Platform for 3D Microfluidic Cancer Research 10/8/2021
- AMSBIO: Aptamers for Targeting SARS-CoV-2 Proteins 9/24/2021
- AMSBIO: Cryopreservation Excipient for Cell Therapies 9/15/2021
- AMSBIO: Defined & Controllable Extracellular Matrix for Cell Culture 8/26/2021
- AMSBIO: Highly Efficient Exosome Isolation & Purification Tools 8/18/2021
- AMSBIO: Biosimilar Products for Research Use 7/28/2021
- AMSBIO: Normal & Disease-State FFPE Tissue Blocks 7/15/2021
- AMSBIO: Using Lentivectors to Label Organoids 7/1/2021
- AMSBIO: New iPSC Model for COVID-19 6/29/2021
- AMSBIO: A New iPSC Model for COVID-19 6/18/2021
- AMSBIO: Developing a Cell Therapy for Parkinson’s Disease 5/26/2021
- AMSBIO: Biotinylated Heparan Sulfate Antibodies 4/29/2021
- AMSBIO: Cytosections for Antibody Screening and Immunohistochemistry Protocol Development 4/15/2021
- AMSBIO: Animal-Free Enzymes for In-Vitro Tissue Dissociation 3/26/2021
- AMSBIO: GMP-Ready Helper Plasmids for AAV Production 3/18/2021
- AMSBIO Announce a New HER2 Control Breast Cancer Cell Line Array 3/4/2021
- AMSBIO: Mutant Spike Proteins & Antigens for SARS-CoV-2 Variant Research 2/18/2021
- AMSBIO: Patient-Derived Human Primary Cancer Cells 2/3/2021